Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23106926 | 0.76 | CYP3A4 (0.37) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL24246241 | 0.75 | TDP1 (0.47) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL16230365 | 0.75 | TDP1 (0.47) | CYP19A1CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL24246245 | 0.66 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL23106981 | 0.65 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL24246200 | 0.65 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL23106982 | 0.62 | SHBG (0.38) | CYP19A1CYP3A4 | |
| SCHEMBL24246201 | 0.62 | SHBG (0.38) | CYP19A1CYP3A4 | |
| SCHEMBL16730562 | 0.62 | SHBG (0.38) | CYP19A1CYP3A4 | |
| SCHEMBL23106925 | 0.61 | CYP19A1 (0.33) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018006-B2 | Method of producing EPD and analogues thereof | VAN HAAFTEN CAROLINE (NL) | 2024-06-25 | — | — | US | disclosed |
| US-20210078965-A1 | METHOD OF PRODUCING EPD AND ANALOGUES THEREOF | VAN HAAFTEN CAROLINE (NL) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018006-B2 | Method of producing EPD and analogues thereof | EPX, EPB41, ERG28 | CYP19A1 169/4885CYP3A4 347/4885CYP2C9 319/4885 |
| US-20210078965-A1 | METHOD OF PRODUCING EPD AND ANALOGUES THEREOF | EPX, EPB41, ERG28 | CYP19A1 169/4885CYP3A4 347/4885CYP2C9 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.